Get the Stockscreener App
1.985
12.78%
0.225
Inhibikase Therapeutics Inc stock is traded at $1.985, with a volume of 31.89M.
It is up +12.78% in the last 24 hours and up +14.08% over the past month.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
See More
Previous Close:
$1.76
Open:
$1.98
24h Volume:
31.89M
Relative Volume:
30.23
Market Cap:
$240.72M
Revenue:
-
Net Income/Loss:
$-19.57M
P/E Ratio:
-0.6342
EPS:
-3.13
Net Cash Flow:
$-17.24M
1W Performance:
+18.86%
1M Performance:
+14.08%
6M Performance:
+5.03%
1Y Performance:
-33.16%
1-Day Range:
$1.89
$2.11
1-Week Range:
$1.65
$2.11
52-Week Range:
$1.33
$2.89
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
Name
Inhibikase Therapeutics Inc
Sector
Industry
Phone
(302) 295-3800
Address
1000 N. WEST STREET, SUITE 1200, WILMINGTON
Compare IKT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.985 | 213.43M | 0 | -19.57M | -17.24M | -3.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.34 | 121.15B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.36 | 82.43B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
828.86 | 52.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.61 | 44.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
365.16 | 40.07B | 4.98B | 69.60M | 525.67M | 0.5198 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-21-26 | Initiated | BofA Securities | Buy |
| Dec-26-25 | Initiated | H.C. Wainwright | Buy |
| Dec-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc Stock (IKT) Latest News
Will Inhibikase Therapeutics Inc. stock deliver consistent dividendsMarket Sentiment Review & Technical Buy Zone Confirmations - mfd.ru
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Does Inhibikase Therapeutics Inc. stock benefit from AI growthChart Signals & Free Expert Approved Momentum Trade Ideas - mfd.ru
Inhibikase Therapeutics (NASDAQ:IKT) Trading Up 6.9%Time to Buy? - MarketBeat
Aug Big Picture: Can Inhibikase Therapeutics Inc sustain its profitability2025 Valuation Update & Entry Point Confirmation Signals - baoquankhu1.vn
What’s next for Inhibikase Therapeutics Inc. stockWeekly Profit Recap & High Conviction Investment Ideas - mfd.ru
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Pfizer (PFE) and Inhibikase Therapeutics (IKT) - The Globe and Mail
Aug Chart Watch: Is Inhibikase Therapeutics Inc a potential multi baggerJuly 2025 WrapUp & Target Return Focused Stock Picks - baoquankhu1.vn
Guidance Update: Is Precision Drilling Corporation affected by consumer sentimentEarnings Overview Summary & Weekly High Potential Alerts - baoquankhu1.vn
Risk Report: Does Inhibikase Therapeutics Inc stock benefit from AI growth2025 Market Outlook & Smart Investment Allocation Insights - baoquankhu1.vn
Market Outlook: Is HCA Healthcare Inc stock a smart retirement pickJuly 2025 Movers & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
What drives Inhibikase Therapeutics Inc.’s stock priceQuarterly Trade Report & Short-Term High Return Ideas - mfd.ru
B of A Securities Initiates Coverage of Inhibikase Therapeutics (IKT) with Buy Recommendation - Nasdaq
BofA Securities initiates coverage on Inhibikase stock with Buy rating By Investing.com - Investing.com South Africa
Inhibikase Therapeutics (NYSE:IKT) Earns Buy Rating from Analysts at Bank of America - MarketBeat
B of A Securities Initiates Coverage on IKT with 'Buy' Rating | - GuruFocus
BofA Securities initiates coverage on Inhibikase stock with Buy rating - Investing.com
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
What analyst consensus says on Inhibikase Therapeutics Inc. stockQuarterly Profit Report & Expert Curated Trade Ideas - Bollywood Helpline
Can Inhibikase Therapeutics Inc. stock sustain free cash flow growthMarket Growth Report & Daily Stock Momentum Reports - bollywoodhelpline.com
RSI Check: Does Inhibikase Therapeutics Inc outperform in volatile marketsMarket Growth Report & High Accuracy Investment Signals - baoquankhu1.vn
Inhibikase Therapeutics (NYSE:IKT) Trading Up 1.2%What's Next? - MarketBeat
Take Profit: Why Inhibikase Therapeutics Inc stock could outperform in 2025 - Bộ Nội Vụ
Published on: 2026-01-14 00:17:08 - Bộ Nội Vụ
How Inhibikase Therapeutics Inc IQT0 stock reacts to stronger dollarSwing Trade & Growth Focused Investment Plans - Bộ Nội Vụ
Why Inhibikase Therapeutics Inc. stock attracts global investorsBest Sellers Snapshot & trail grip notes for mixed terrain - Улправда
How Inhibikase Therapeutics Inc. stock performs in weak economyMarket Weekly Review & Technical Entry and Exit Tips - Улправда
Is Inhibikase Therapeutics Inc. stock attractive for passive investorsPortfolio Update Report & Weekly Watchlist of Top Performers - ulpravda.ru
Can Inhibikase Therapeutics Inc. stock sustain institutional interestJuly 2025 PostEarnings & Stepwise Trade Execution Plans - Улправда
How Inhibikase Therapeutics Inc. (IQT0) stock reacts to stronger dollarWeekly Loss Report & Safe Entry Point Identification - Улправда
Can Inhibikase Therapeutics Inc. (IQT0) stock surprise with quarterly results2025 Key Lessons & Low Drawdown Trading Strategies - Улправда
Published on: 2026-01-08 18:28:15 - ulpravda.ru
Inhibikase Halts Parkinson's Drug Development to Focus on PAH - MSN
Is Inhibikase Therapeutics Inc. stock attractive for income investorsHealthcare Stock Analysis & Budget Investment Success - Улправда
Laser Focus WorldInhibikase Therapeutics, Inc.Common Stock (Nasdaq:IKT) Stock Quote - FinancialContent
Dopamine Agonists Market is expected to reach US$ 1,732.41 - openPR.com
Inhibikase Therapeutics (NYSE:IKT) & Alpha Cognition (OTC:ACOGF) Head-To-Head Review - Defense World
Critical Survey: Liminatus Pharma (NASDAQ:LIMN) vs. Inhibikase Therapeutics (NASDAQ:IKT) - Defense World
Comparing Liminatus Pharma (NASDAQ:LIMN) & Inhibikase Therapeutics (NASDAQ:IKT) - Defense World
While Institutions Invested in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Benefited From Last Week's 24% Gain, Retail Investors Stood to Gain the Most - 富途牛牛
Inhibikase Therapeutics (NASDAQ:IKT) versus Liminatus Pharma (NASDAQ:LIMN) Head to Head Comparison - Defense World
Short Interest in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Rises By 29.0% - MarketBeat
Inhibikase Therapeutics (NASDAQ:IKT) vs. Liminatus Pharma (NASDAQ:LIMN) Financial Survey - Defense World
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Rating of “Buy” by Analysts - Defense World
Jefferies reiterates Buy rating on Inhibikase stock, citing faster FDA path By Investing.com - Investing.com Nigeria
Jefferies reiterates Buy rating on Inhibikase stock, citing faster FDA path - Investing.com Nigeria
Inhibikase Therapeutics (NASDAQ:IKT) Raised to “Strong-Buy” at HC Wainwright - Defense World
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Inhibikase Therapeutics (NASDAQ:IKT) Raised to "Strong-Buy" at HC Wainwright - MarketBeat
Inhibikase Therapeutics Inc Stock (IKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.14%
1.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):